SG151288A1 - 3-cyano-quinoline derivatives with antiproliferative activity - Google Patents

3-cyano-quinoline derivatives with antiproliferative activity

Info

Publication number
SG151288A1
SG151288A1 SG200901893-8A SG2009018938A SG151288A1 SG 151288 A1 SG151288 A1 SG 151288A1 SG 2009018938 A SG2009018938 A SG 2009018938A SG 151288 A1 SG151288 A1 SG 151288A1
Authority
SG
Singapore
Prior art keywords
cyano
antiproliferative activity
quinoline derivatives
compounds
formula
Prior art date
Application number
SG200901893-8A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Peter Jacobus Johannes Antonius Buijnsters
Emelen Kristof Van
Werner Constant Johan Embrechts
Timothy Pietro Suren Perera
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG151288(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG151288A1 publication Critical patent/SG151288A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG200901893-8A 2003-12-18 2004-12-15 3-cyano-quinoline derivatives with antiproliferative activity SG151288A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51059 2003-12-18

Publications (1)

Publication Number Publication Date
SG151288A1 true SG151288A1 (en) 2009-04-30

Family

ID=34684508

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200901893-8A SG151288A1 (en) 2003-12-18 2004-12-15 3-cyano-quinoline derivatives with antiproliferative activity

Country Status (23)

Country Link
US (4) US7655642B2 (es)
EP (1) EP1696914B1 (es)
JP (1) JP4892353B2 (es)
KR (1) KR101158440B1 (es)
CN (1) CN1893944B (es)
AR (1) AR047060A1 (es)
AT (1) ATE446750T1 (es)
AU (1) AU2004298784B2 (es)
BR (1) BRPI0417609B8 (es)
CA (1) CA2549728C (es)
DE (1) DE602004023876D1 (es)
EA (1) EA200601176A1 (es)
ES (1) ES2335216T3 (es)
HK (1) HK1095742A1 (es)
IL (1) IL176358A (es)
MX (1) MXPA06007018A (es)
NO (1) NO337622B1 (es)
NZ (1) NZ547795A (es)
SG (1) SG151288A1 (es)
TW (2) TWI374879B (es)
UA (1) UA83880C2 (es)
WO (1) WO2005058318A1 (es)
ZA (1) ZA200604971B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305887T3 (es) * 2003-12-18 2008-11-01 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos.
KR101158440B1 (ko) * 2003-12-18 2012-07-06 얀센 파마슈티카 엔.브이. 항증식활성을 지닌 3-시아노-퀴놀린 유도체
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
JP5380073B2 (ja) * 2005-11-16 2014-01-08 エス*バイオ プライベート リミティッド ヘテロアルキル結合ピリミジン誘導体
AU2007274284B2 (en) * 2006-07-13 2012-04-26 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
CA2687909C (en) * 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
JP5536647B2 (ja) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028613A (en) 1990-02-16 1991-07-02 Repligen Corporation Novel pyrroloquinoline alkaloids and methods of use
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PT1117659E (pt) 1998-09-29 2004-04-30 Wyeth Corp Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
AU2003226705B2 (en) * 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
KR101158440B1 (ko) 2003-12-18 2012-07-06 얀센 파마슈티카 엔.브이. 항증식활성을 지닌 3-시아노-퀴놀린 유도체

Also Published As

Publication number Publication date
KR20070005560A (ko) 2007-01-10
CA2549728C (en) 2015-07-21
US20130197022A1 (en) 2013-08-01
WO2005058318A1 (en) 2005-06-30
HK1095742A1 (en) 2007-05-18
US20080139601A1 (en) 2008-06-12
TWI374879B (en) 2012-10-21
JP4892353B2 (ja) 2012-03-07
MXPA06007018A (es) 2006-08-31
BRPI0417609B1 (pt) 2019-02-19
US20140256948A1 (en) 2014-09-11
BRPI0417609A (pt) 2007-04-10
EA200601176A1 (ru) 2006-10-27
JP2007514711A (ja) 2007-06-07
US9365517B2 (en) 2016-06-14
TWI389890B (zh) 2013-03-21
AU2004298784B2 (en) 2011-06-09
IL176358A (en) 2010-06-16
ZA200604971B (en) 2009-05-27
NO20063324L (no) 2006-07-18
NZ547795A (en) 2009-07-31
CA2549728A1 (en) 2005-06-30
TW201132628A (en) 2011-10-01
BRPI0417609B8 (pt) 2021-05-25
DE602004023876D1 (de) 2009-12-10
US8778920B2 (en) 2014-07-15
EP1696914A1 (en) 2006-09-06
CN1893944A (zh) 2007-01-10
TW200530187A (en) 2005-09-16
EP1696914B1 (en) 2009-10-28
ATE446750T1 (de) 2009-11-15
CN1893944B (zh) 2011-07-06
US7655642B2 (en) 2010-02-02
IL176358A0 (en) 2006-10-05
KR101158440B1 (ko) 2012-07-06
ES2335216T3 (es) 2010-03-23
US20100069424A1 (en) 2010-03-18
US9040511B2 (en) 2015-05-26
UA83880C2 (en) 2008-08-26
AU2004298784A1 (en) 2005-06-30
NO337622B1 (no) 2016-05-09
AR047060A1 (es) 2006-01-04

Similar Documents

Publication Publication Date Title
NO20063324L (no) 3-cyano-kinolinderivater med antiproliferativ aktivitet
GB0124933D0 (en) Chemical compounds
UA84010C2 (en) Macrocyclic quinazoline derivatives as antiproliferative agents
DE60112974D1 (en) Carbolinderivate
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
IL163781A0 (en) Purine derivatives as kinase inhibitors
MY141196A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
SI1771178T1 (sl) Uporaba K-252a in kinaznih inhibitorjev za preprečevanje ali zdravljenje patologij, povezanih s HMGB1
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2006061417A3 (en) Macrocyclic quinazole derivatives and their use as mtki
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
MY132106A (en) New pyridazin-3(2h)-one derivatives
DE60216233D1 (en) Carbolinderivate
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
HK1118534A1 (en) Thieno-pyrimidine compounds having fungicidal activity
WO2007120333A3 (en) Tetracyclic kinase inhibitors
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
MXPA03002911A (es) Compuestos quimicos.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
TW200628153A (en) Novel compounds
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents